SCHEMBL9545171

SCHEMBL9545171

CC(C)(C)OC(=O)Cn1cnc2c(Cl)ncnc21

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 3/20 0.56
FDPS P14324 1/20 0.49
FGFR1 P11362 9/20 0.47
FGFR4 P22455 9/20 0.47
HDAC6 Q9UBN7 2/20 0.47
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
PI4KA P42356 1/20 0.42
PI4K2B Q8TCG2 1/20 0.42
PI4K2A Q9BTU6 1/20 0.42
PI4KB Q9UBF8 1/20 0.42
CCNE2 O96020 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
EGFR P00533 1/20 0.39
SLC29A1 Q99808 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6805557 0.87 P2RX7 (0.48) P2RX7FDPSFGFR1FGFR4HDAC6
SCHEMBL9435719 0.84 PI4KA (0.62) KDRPI4KAPI4K2BPI4K2API4KB
SCHEMBL22412661 0.83 P2RX7 (0.55) P2RX7HDAC6CCNE2CCNE1CDK2
SCHEMBL28020916 0.80 P2RX7 (0.64) P2RX7FDPSFGFR1FGFR4HDAC6
SCHEMBL4640082 0.79 FGFR1 (0.47) P2RX7FDPSFGFR1FGFR4HDAC6
SCHEMBL9544785 0.79 FPR2 (0.37) P2RX7HDAC6KDRCCNE2CCNE1
SCHEMBL23885424 0.79 P2RX7 (0.66) P2RX7FDPSFGFR1FGFR4HDAC6
SCHEMBL30254206 0.79 P2RX7 (0.53) P2RX7FDPSFGFR1FGFR4HDAC6
SCHEMBL30015306 0.78 FPR2 (0.43) P2RX7HDAC6CCNE2CCNE1CDK2
SCHEMBL23558005 0.78 FPR2 (0.43) P2RX7HDAC6CCNE2CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 US disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 CN disclosed
US-20210163484-A1 METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES UNIVERSITÉ GRENOBLE ALPES (FR) 2021-06-03 US disclosed
WO-1993018035-A1 ANGIOTENSIN II RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 1993-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163484-A1 METHOD FOR SYNTHESIZING DIVERSELY SUBSTITUTED PURINES PNP, UMPS, NUDT1 P2RX7 144/4885FDPS 25/4885FGFR1 981/4885
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP P2RX7 659/4885FDPS 120/4885FGFR1 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.